Payment overview · 2025
General Payments
$700.08
31 reported records · 10 companies
Healthcare provider profile · identity verified
Abraham Samuel Dubb, MD
Allopathic & Osteopathic Physicians|Internal Medicine · PHILADELPHIA, PA · NPI 1184637936
Verified facts
What the public records show
CMS Open Payments records show Abraham Samuel Dubb, MD received $700.08 in general payments during 2025 across 31 reported records.
Gilead Sciences, Inc. accounted for 41.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Linzess by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 196 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 132 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $291.11 | 41.6% | 13 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $141.08 | 20.1% | 7 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $50.59 | 7.2% | 2 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $39.32 | 5.6% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $37.15 | 5.3% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $34.54 | 4.9% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $31.50 | 4.5% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $30.90 | 4.4% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $22.44 | 3.2% | 1 | 2025 |
| Hologic Sales and Service, LLC | Unresolved — no canonical attribution shown | $21.45 | 3.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $700.08 | 31 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $59.32 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $59.32 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $50.59 | 2 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $39.32 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $37.15 | 2 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $37.15 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $34.54 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $31.50 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $30.90 | 1 | 2025 |
Source payment records
|
|||||
| Yeztugo Normalized: yeztugo |
Drug | Gilead Sciences, Inc. | $29.25 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $22.44 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $22.44 | 1 | 2025 |
Source payment records
|
|||||
| APTIMA Normalized: aptima |
Device | Hologic Sales and Service, LLC | $21.45 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $18.43 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 132 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 52 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
48 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
196 | 36 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
132 | 29 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
52 | 12 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
76 | 24 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 862 | 241 |
| Amlodipine Besylate | Amlodipine Besylate | 647 | 162 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 424 | 118 |
| Gabapentin | Gabapentin | 388 | 111 |
| Losartan Potassium | Losartan Potassium | 379 | 117 |
| Omeprazole | Omeprazole | 363 | 89 |
| Lisinopril | Lisinopril | 333 | 97 |
| Fluticasone Propionate | Fluticasone Propionate | 292 | 74 |
| Metoprolol Succinate | Metoprolol Succinate | 253 | 81 |
| Hydrochlorothiazide | Hydrochlorothiazide | 214 | 51 |
| Carvedilol | Carvedilol | 211 | 48 |
| Levothyroxine Sodium | Levothyroxine Sodium | 203 | 50 |
| Trulicity | Dulaglutide | 196 | 36 |
| Furosemide | Furosemide | 179 | 52 |
| Januvia | Sitagliptin Phosphate | 172 | 39 |
| Pantoprazole Sodium | Pantoprazole Sodium | 169 | 49 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 169 | 55 |
| Metformin Hcl | Metformin Hcl | 159 | 55 |
| Breo Ellipta | Fluticasone/Vilanterol | 150 | 29 |
| Metformin Hcl Er | Metformin Hcl | 145 | 37 |
| Trazodone Hcl | Trazodone Hcl | 141 | 32 |
| Mirtazapine | Mirtazapine | 137 | 42 |
| Tamsulosin Hcl | Tamsulosin Hcl | 137 | 47 |
| Ozempic | Semaglutide | 132 | 29 |
| Montelukast Sodium | Montelukast Sodium | 125 | 20 |
| Escitalopram Oxalate | Escitalopram Oxalate | 121 | 43 |
| Farxiga | Dapagliflozin Propanediol | 121 | 27 |
| Sertraline Hcl | Sertraline Hcl | 117 | 27 |
| Famotidine | Famotidine | 107 | 22 |
| Duloxetine Hcl | Duloxetine Hcl | 103 | 23 |
| Pravastatin Sodium | Pravastatin Sodium | 94 | 27 |
| Pregabalin | Pregabalin | 94 | 20 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 93 | 25 |
| Nifedipine Er | Nifedipine | 90 | 23 |
| Quetiapine Fumarate | Quetiapine Fumarate | 88 | 20 |
| Allopurinol | Allopurinol | 85 | 19 |
| Clopidogrel | Clopidogrel Bisulfate | 85 | 22 |
| Finasteride | Finasteride | 80 | 20 |
| Eliquis | Apixaban | 76 | 24 |
| Alendronate Sodium | Alendronate Sodium | 75 | 29 |
| Hydralazine Hcl | Hydralazine Hcl | 72 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 70 | 24 |
| Bupropion Xl | Bupropion Hcl | 65 | 15 |
| Meloxicam | Meloxicam | 64 | 18 |
| Diclofenac Sodium | Diclofenac Sodium | 62 | 13 |
| Metoprolol Tartrate | Metoprolol Tartrate | 61 | 20 |
| Novolog Flexpen | Insulin Aspart | 61 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 56 | 19 |
| Naproxen | Naproxen | 54 | 11 |
| Glimepiride | Glimepiride | 53 | 12 |
| Ibuprofen | Ibuprofen | 53 | 23 |
| Tramadol Hcl | Tramadol Hcl | 53 | 15 |
| Meclizine Hcl | Meclizine Hcl | 52 | 14 |
| Rybelsus | Semaglutide | 52 | 12 |
| Clonazepam | Clonazepam | 51 | 12 |
| Glipizide Er | Glipizide | 51 | 12 |
| Enalapril Maleate | Enalapril Maleate | 50 | suppressed |
| Nystatin | Nystatin | 49 | suppressed |
| Glipizide | Glipizide | 48 | 16 |
| Jardiance | Empagliflozin | 48 | 17 |
| Loperamide | Loperamide Hcl | 48 | suppressed |
| Potassium Chloride | Potassium Chloride | 47 | 13 |
| Celecoxib | Celecoxib | 46 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 46 | 13 |
| Lorazepam | Lorazepam | 44 | 14 |
| Risperidone | Risperidone | 43 | suppressed |
| Ezetimibe | Ezetimibe | 41 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 40 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 39 | 13 |
| Azelastine Hcl | Azelastine Hcl | 38 | suppressed |
| Entresto | Sacubitril/Valsartan | 38 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 38 | suppressed |
| Simvastatin | Simvastatin | 38 | 15 |
| Valsartan | Valsartan | 38 | 14 |
| Spiriva Handihaler | Tiotropium Bromide | 37 | suppressed |
| Bumetanide | Bumetanide | 36 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 32 | suppressed |
| Lidocaine | Lidocaine | 32 | suppressed |
| Xarelto | Rivaroxaban | 32 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 31 | suppressed |
| Lovastatin | Lovastatin | 31 | suppressed |
| Azithromycin | Azithromycin | 30 | 24 |
| Ketoconazole | Ketoconazole | 30 | suppressed |
| Levetiracetam | Levetiracetam | 29 | suppressed |
| Ondansetron Odt | Ondansetron | 29 | 15 |
| Aripiprazole | Aripiprazole | 28 | suppressed |
| Tradjenta | Linagliptin | 28 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 27 | suppressed |
| Topiramate | Topiramate | 27 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 27 | 11 |
| Atenolol | Atenolol | 26 | suppressed |
| Baclofen | Baclofen | 26 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 25 | suppressed |
| Chlorthalidone | Chlorthalidone | 25 | suppressed |
| Colchicine | Colchicine | 25 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 25 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 24 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 24 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 23 | suppressed |
| Cilostazol | Cilostazol | 23 | suppressed |
| Diazepam | Diazepam | 23 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 23 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 22 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 22 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 22 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 21 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 21 | suppressed |
| Methimazole | Methimazole | 21 | suppressed |
| Temazepam | Temazepam | 21 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 21 | suppressed |
| Calcitriol | Calcitriol | 20 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 20 | suppressed |
| Fluocinolone Acetonide | Fluocinolone Acetonide | 20 | 12 |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 20 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 19 | suppressed |
| Linzess | Linaclotide | 19 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 18 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 18 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 18 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 18 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 18 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 17 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 17 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 17 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 17 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 16 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Calcium Acetate | Calcium Acetate | 16 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 16 | suppressed |
| Myrbetriq | Mirabegron | 16 | suppressed |
| Spironolactone | Spironolactone | 16 | suppressed |
| Sulfasalazine | Sulfasalazine | 16 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 15 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 15 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 15 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 15 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Alprazolam | Alprazolam | 14 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 14 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 14 | suppressed |
| Prednisone | Prednisone | 14 | 14 |
| Velphoro | Sucroferric Oxyhydroxide | 14 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 13 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 13 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 13 | suppressed |
| Methylprednisolone | Methylprednisolone | 13 | 13 |
| Midodrine Hcl | Midodrine Hcl | 13 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 13 | suppressed |
| Sotalol | Sotalol Hcl | 13 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 13 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 12 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $700.08 · 31 records | Gilead Sciences, Inc. | APTIMA, Cologuard Collection Kit, EVENITY, Leqembi, MOUNJARO, NURTEC ODT, Ozempic, PROLIA, Rybelsus, TZIELD, VRAYLAR, Wegovy, Yeztugo, ZAVZPRET | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error